Abstract
Neuroglobin (Ngb) has been demonstrated to be neuroprotective against stroke and neurodegenerative diseases, thus upregulating Ngb might be a novel approach for neuroprotection. In this study we aimed to establish cell-based Ngb reporter systems for screening neuroprotective compounds targeting Ngb upregulation. We developed both mouse and human stable Ngb reporter systems containing a luciferase reporter gene directed by mouse and human Ngb promoter, respectively. To validate these reporter systems, we used them to screen a pool of natural plant compounds. RT-PCR was used to verify the Ngb-upregulating effects of selected compounds, and neurotoxicity assay was used to test their neuroprotection effects in primary cultured neurons. We identified polydatin, genistein, daidzein, biochanin A and formononetin that can upregulate both mouse and human Ngb promoter activity. RT-PCR confirmed that polydatin, genistein and formononetin significantly increased Ngb mRNA expression in primary neurons. Furthermore, formononetin significantly decreased oxygen-glucose deprivation (OGD)-induced neurotoxicity. Moreover, inhibition of cAMP response element-binding protein (CREB) showed that CREB is required for formononetin-induced Ngb upregulation. These results suggest that these Ngb reporter systems are suitable for neuroprotective compound screening, which will be used to screen larger compound libraries for more potent neuroprotectants. This preliminary study will facilitate the development of Ngb-targeted therapeutics for stroke and neurodegenerative diseases.
Keywords: High-throughput screening, luciferase reporter assay, neurodegeneration, neuroglobin (Ngb), neuroprotection, Ngb promoter, primary neuron.
CNS & Neurological Disorders - Drug Targets
Title:Establishment of Cell-Based Neuroglobin Promoter Reporter Assay for Neuroprotective Compounds Screening
Volume: 15 Issue: 5
Author(s): Ning Liu, Zhanyang Yu, Xiumei Gao, Yun S. Song, Jing Yuan, Yu Xun, Tingting Wang, Feng Yan, Shishan Yuan, Jian Zhang, Shuanglin Xiang, Eng H. Lo and Xiaoying Wang
Affiliation:
Keywords: High-throughput screening, luciferase reporter assay, neurodegeneration, neuroglobin (Ngb), neuroprotection, Ngb promoter, primary neuron.
Abstract: Neuroglobin (Ngb) has been demonstrated to be neuroprotective against stroke and neurodegenerative diseases, thus upregulating Ngb might be a novel approach for neuroprotection. In this study we aimed to establish cell-based Ngb reporter systems for screening neuroprotective compounds targeting Ngb upregulation. We developed both mouse and human stable Ngb reporter systems containing a luciferase reporter gene directed by mouse and human Ngb promoter, respectively. To validate these reporter systems, we used them to screen a pool of natural plant compounds. RT-PCR was used to verify the Ngb-upregulating effects of selected compounds, and neurotoxicity assay was used to test their neuroprotection effects in primary cultured neurons. We identified polydatin, genistein, daidzein, biochanin A and formononetin that can upregulate both mouse and human Ngb promoter activity. RT-PCR confirmed that polydatin, genistein and formononetin significantly increased Ngb mRNA expression in primary neurons. Furthermore, formononetin significantly decreased oxygen-glucose deprivation (OGD)-induced neurotoxicity. Moreover, inhibition of cAMP response element-binding protein (CREB) showed that CREB is required for formononetin-induced Ngb upregulation. These results suggest that these Ngb reporter systems are suitable for neuroprotective compound screening, which will be used to screen larger compound libraries for more potent neuroprotectants. This preliminary study will facilitate the development of Ngb-targeted therapeutics for stroke and neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Liu Ning, Yu Zhanyang, Gao Xiumei, S. Song Yun, Yuan Jing, Xun Yu, Wang Tingting, Yan Feng, Yuan Shishan, Zhang Jian, Xiang Shuanglin, H. Lo Eng and Wang Xiaoying, Establishment of Cell-Based Neuroglobin Promoter Reporter Assay for Neuroprotective Compounds Screening, CNS & Neurological Disorders - Drug Targets 2016; 15 (5) . https://dx.doi.org/10.2174/1871527315666160321105612
DOI https://dx.doi.org/10.2174/1871527315666160321105612 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents
Current Clinical Pharmacology Circulating Microparticles as Therapeutic Targets in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study
Current Alzheimer Research A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity
CNS & Neurological Disorders - Drug Targets SAGE Application in the Study of Diabetes
Current Pharmaceutical Biotechnology Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure- Activity Relationships of a Neuroprotective Peptide
Current Medicinal Chemistry The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Current Pharmaceutical Design Chromogranins and Inositol 1,4,5-Trisphosphate-Dependent Ca2+-Signaling in Cardiomyopathy and Heart Failure
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Drug Targets Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Candidate Susceptibility Genes in Alzheimers Disease Are at High Risk for Being Forgotten - They Dont Give Peace of Mind...
Current Drug Metabolism Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology A Review of Probiotic Supplementation and Feasibility of Topical Application for the Treatment of Pediatric Atopic Dermatitis
Current Pharmaceutical Biotechnology Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Prospective Approaches of Herbal Novel Delivery System with Special Reference to the Herbal Nanosciences
Current Drug Therapy <i>In Vivo/Ex Vivo</i> EPR Investigation of the Brain Redox Status and Blood-Brain Barrier Integrity in the 5xFAD Mouse Model of Alzheimer's Disease
Current Alzheimer Research